The leading Migraine Companies such as ​ Satsuma Pharmaceuticals, Biohaven Pharmaceuticals, Allodynic Therapeutics, Vaxxinity ...

CompanyOverview|NASDAQ:VKTX] Viking Therapeutics Inc. (NASDAQ: VKTX) reported earnings after the market closed on Apr. 23.

Metsera's lead asset is MET-097i, billed as an ultra-long-acting GLP-1 receptor agonist with a profile that could challenge Novo Nordisk's Wegovy (semaglutide) and Eli Lilly's Zepbound ...

half-life, which Metsera said was at least as good as approved and clinical-stage drugs in the class, which include Novo Nordisk's Wegovy (semaglutide) and Eli Lilly's Zepbound (tirzepatide).

Given the potential opportunities in the sector, should investors buy Eli Lilly stock? Here's where the company and its stock stand now. The GLP-1 agonist opportunity is gearing up for its next ...

The weight loss drug market could grow to $500 billion over the next decade. Eli Lilly's next-generation products look promising, while competitors have stumbled in clinical trials. Investors are ...

Eli Lilly's oral GLP-1 medicine aced a phase 3 study. It should become a new growth driver for the company. There are other reasons to invest in the pharmaceutical leader. Zepbound's prospects ...

The most recent trading session ended with Eli Lilly (LLY) standing at $827.54, reflecting a +1.16% shift from the previouse trading day's closing. The stock lagged the S&P 500's daily gain of 2.51%.

Eli Lilly is suing four telehealth companies that prescribe compounded versions of the pharmaceutical company's weight loss medications. Lilly filed four lawsuits on Wednesday claiming telehealth ...

Tom Brady and Eli Manning's unexpected rivalry is defined by Super Bowl clashes, where Manning twice thwarted Brady's dominance. Manning's Giants upset Brady's Patriots in Super Bowls XLII and ...

Eli Lilly is suing four telemedicine companies selling compounded versions of its blockbuster obesity drug Zepbound and its diabetes treatment Mounjaro, escalating its battle against unauthorized ...